Related references
Note: Only part of the references are listed.Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42)
Kazuya Fujihara et al.
MEDICINE (2017)
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials
Wenjia Yang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes
H. -H. Chen et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2016)
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
Hisamitsu Ishihara et al.
DIABETES OBESITY & METABOLISM (2016)
Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes
J. -L. Faillie et al.
DIABETES OBESITY & METABOLISM (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
The New insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes
Yunjuan Zhao et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infections
Ana Esparcia et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research
Elizabeth A. Stuart et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
Dipeptidyl peptidase-4: A key player in chronic liver disease
Minoru Itou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
Marjolein J. Willemen et al.
DIABETES CARE (2011)
Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Nasser Mikhail
CURRENT DRUG SAFETY (2011)
The epidemiology of urinary tract infection
Betsy Foxman
NATURE REVIEWS UROLOGY (2010)
Host-pathogen interactions in urinary tract infection
Greta R. Nielubowicz et al.
NATURE REVIEWS UROLOGY (2010)
Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
E. Matteucci et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Role of CD26/dipeptidyl peptidase IV in human T cell activation and function
Kei Ohnuma et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Incretin-based therapies in type 2 diabetes mellitus
Chee W. Chia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
V Sundararajan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Share Paper
